Optimising use of thiopurines in inflammatory bowel disease

TY - JOUR

T1 - Optimising use of thiopurines in inflammatory bowel disease

AU - Dart, Robin J.

AU - Irving, Peter M.

N1 - Funding Information: P Irving has received lecture fees from Abbvie, Warner Chilcott, Ferring, Falk Pharma, Takeda, MSD, Janssen, Shire and Tillotts; financial support for research from MSD, Takeda and Janssen and advisory fees from Abbvie, Warner Chilcott, Takeda, MSD, Vifor Pharma, Pharmacosmos, Topivert, Genentech, Hospira, Samsung Bioepis, Janssen and VH2. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2017 Informa UK Limited, trading as Taylor & Francis Group. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 2017/9/2

Y1 - 2017/9/2

N2 - Introduction: Thiopurines are central to inflammatory bowel disease (IBD) therapeutics, either as monotherapy or in combination with newer biologic therapies, however it is only recently that focus has increased on improving effectiveness and tolerability through optimisation. Areas covered: We review the role of thiopurines in IBD and the importance of the timing of initiation of therapy. Drug metabolism and pharmacogenetics have increasingly played a role in determining dosing and dose optimisation and we review the rationale for this in both thiopurine monotherapy and in combination with biologic agents. We also discuss allopurinol co-therapy as a strategy for enhancing both efficacy and tolerability of thiopurine therapy. Although immunomodulators carry safety considerations, we discuss methods of optimisation to minimise side-effects and maximise safety to ensure the broadest number of patients can benefit. Expert commentary: We provide a practical guide to drug initiation and dose optimisation in a clinical setting, and address potential treatment duration. The forward view considers the place for thiopurines in the treatment of IBD, and how the application of the plethora of genetic data may help inform thopurine therapy in the future.

AB - Introduction: Thiopurines are central to inflammatory bowel disease (IBD) therapeutics, either as monotherapy or in combination with newer biologic therapies, however it is only recently that focus has increased on improving effectiveness and tolerability through optimisation. Areas covered: We review the role of thiopurines in IBD and the importance of the timing of initiation of therapy. Drug metabolism and pharmacogenetics have increasingly played a role in determining dosing and dose optimisation and we review the rationale for this in both thiopurine monotherapy and in combination with biologic agents. We also discuss allopurinol co-therapy as a strategy for enhancing both efficacy and tolerability of thiopurine therapy. Although immunomodulators carry safety considerations, we discuss methods of optimisation to minimise side-effects and maximise safety to ensure the broadest number of patients can benefit. Expert commentary: We provide a practical guide to drug initiation and dose optimisation in a clinical setting, and address potential treatment duration. The forward view considers the place for thiopurines in the treatment of IBD, and how the application of the plethora of genetic data may help inform thopurine therapy in the future.

KW - azathioprine

KW - Crohn’s disease

KW - inflammatory bowel disease

KW - optimisation

KW - Thiopurine

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85028607676&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2017.1351298

DO - 10.1080/1744666X.2017.1351298

M3 - Review article

C2 - 28678626

AN - SCOPUS:85028607676

SN - 1744-666X

VL - 13

SP - 877

EP - 888

JO - Expert Review Of Clinical Immunology

JF - Expert Review Of Clinical Immunology

IS - 9

ER -